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AN AHP APPROACH FOR BALANCING EFFICIENCY AND EQUITY IN THE
UNITED STATES LIVER TRANSPLANTATION SYSTEM: A PILOT STUDY
Vijayachandran M. Veerachandran
ABSTRACT

Liver transplantation and allocation has been a controversial issue in the United
States for decades. One of the main concerns in the allocation system is the trade-off
between the two main objectives, efficiency and equity. Unfortunately, it is difficult to
reach consensus on how to develop allocation policies that aim at balancing efficiency
and equity, among transplantation policy makers, administrators, transplant surgeons and
transplant candidates.
Our research identifies and classifies the outcomes of liver allocation into two
major categories, efficiency and equity, that are, often times, conflicting. Previous
researchers did not consider how to balance outcomes in these two categories. Our
research uses Analytic Hierarchy Process, a Multi-Criteria Decision Analysis
methodology, to build a framework that quantifies the decision-making process and help
decision makers to reach a valid consensus in terms of balancing these outcomes. Latest
available patient registration and follow-up data are used in data analysis. Results from

v

This research addresses the deficiencies of the current liver transplantation policy
and is intended to refine the policy that will result in a more balanced allocation system
with respect to efficiency and equity. Our proposed methodology can be applied to
incorporate further changes in policy selection and refinement.
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CHAPTER 1
INTRODUCTION

1.1 Current Health-Care Scenario in the United States
Improved public health policy and improvements in medical care have increased
the life expectancy of the average American from 49 years in 1900 to an all time high of
77.4 years in 2002 [1]. More amounts are spend for health-care awareness and
improvement. The United States remains the leading nation in global healthcare
spending: an average of $ 4,500 per person [2]. On a per capita basis, health spending in
the U.S. is 50% higher than in the second-highest spending country, Switzerland,
according to the Organization of Economic Co-operation and Development (OECD)
figures [3]. In 2005 the U.S. healthcare industry grew as a more demanding population
sought the best healthcare they could afford. The Center for Medicare and Medicaid
Services (CMS) reports that health care expenditure in the United States is expected to
continue growing to 16.2% of the Gross Domestic Product (GDP) in 2005, up from 16%
in 2004 [4] [7]. By 2015 health care expenditure in the United States is projected to reach
$4 trillion and contributes to 20% of the GDP [5]. This makes the health-service industry
the largest in the U.S. The aforementioned data suggests that even a small improvement
in health-care or associated services might have significant effect on the overall economy
and life expectancy.
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World Health Organization (WHO) statistics show that the U.S. ranks 37th out of
191 countries in performance metrics for overall levels of population health, system
responsiveness, health inequalities or disparities among the population and distribution of
the financial burden [6]. In 2005, the costs of health insurance premiums continued to rise
in the U.S., rising costs are likely to affect the country's healthcare industry [7]. The U.S.
Census Bureau stated that 46 million Americans now lack health insurance. Expenditure
on health services more than doubled in 2005 from ten years earlier. Rising costs of a
health insurance is a growing concern; more and more people are living without adequate
health insurance, Nearly 46 million people in U.S. have no health insurance, which
means these individuals will be deprived of proper treatment solutions in times of
necessity [8].
The Business Communication Company (BCC) reports that more than half of the
health care expenditure in the United States are for organ failures or tissue loss, an
amount that exceeds $600 billion [9]. They also reported that over 215,000 people die in
the U.S. every year from diseases that are treatable with transplantation. The National
Foundation for Transplants reports the average cost for a kidney transplant ranges from
$75,000 to $100,000, liver transplants from $250,000 to $275,000 and lung transplants
from $200,000 to $250,000. The U.S. Organ transplantation was a $4.2 billion market in
2002 of which 76% is attributed to kidney and liver transplantation. The market is
projected to grow at a rate of 5% to $5.4 billion by 2007 [9].
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1.2 Organ Allocation in the U.S.
An organ transplant is the transplantation of a whole or partial organ from one
body to another, for the purpose of replacing the recipient's damaged or failing organ
with a functioning one from the donor. Organ donors can be living, or cadaveric. In the
United States, there's a great shortage of donor organs: hearts, livers, lungs, kidneys,
pancreases and small intestines. Even though there is an increase in the number of
transplants and available livers for transplantation, there is wide disparity between the
number of organs needed for transplantation and number of organs available. Over
92,000 Americans are currently waiting for an organ transplant at any given day, and this
number is increasing and is expected to reach 100,000 by the end of 2010 [10]. In 2005,
only about 28,000 organ transplants were performed. On average, 114 people are added
to the nation's organ transplant waiting list each day -- one every 13 minutes. Nearly
6,500 people died in 2005 because no organs were available.
Lack of available donors in this country lead to the death of 3,886 kidney patients,
1,811 liver patients, 457 heart patients and 483 lung patients in 2004 while waiting for
life-saving organ transplants. Almost 10 percent of the patients currently waiting for liver
transplants are young people under 18 years of age. On November 30, 2001, 2,348
children under age 18 were registered on the organ transplant waiting list. Candidates for
kidney transplants top the waiting list followed by liver candidates and lung candidates
published by the United Network for Organ Sharing (UNOS),
Our research focuses on the study of liver transplantation. Liver transplantation
remains the only treatment for end-stage liver disease (ESLD); however the number of
patients who could benefit from a transplant far exceeds the number of available
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cadaveric donors. There is a wide disparity in the allocation of organs based on various
characteristics for example patients with type O blood wait the longest for a liver
transplant--an average of 1,243 days [13]. People with type AB wait the shortest time--an
average of 210 days. Waiting time has clinically and statistically significant effect on the
probability of graft failure outcomes following transplantation. For every fifty days of
wait time on the list for a transplant the probability of graft failure at one year increases
in between 1% and 2%.

1.2.1 United Network for Organ Sharing
The United Network for Organ Sharing (UNOS) manages the nation's organ
transplant system and oversees a comprehensive database of clinical transplant
information under a contract with the federal government. UNOS maintains and operates
the computerized organ sharing system by matching donated organs to patients registered
on the national organ transplant waiting list. UNOS seeks to increase organ donation
through the education of the public to the dire need of organ transplants and the
improvement of transplant success rates through outcomes-based research and
policymaking [14]. The strength of the transplant database relies on the active reporting
of 412 UNOS member institutions.

1.3 Liver Transplantation
Liver transplantation is necessary for the cure of most causes of acute or chronic
liver disease. Liver transplantation is appropriate to any acute or chronic condition
resulting in irreversible liver dysfunction, provided that the recipient does not have other
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circumstances that will preclude a successful transplant. Cirrhosis is the main reason for
more than 80% of transplantations performed in adults, (hepatitis C and alcoholic liver
disease are the two most common diagnoses). According to (UNOS), there are more than
17,000 patients on the national waiting list for a liver transplant. Yet, in 2002, only 5,329
liver transplantations were performed [14]. The large disparity between the number of
available deceased donor organs and qualified recipients awaiting liver transplantation
has created ongoing debate about selection criteria, the timing of transplantation, and
attempts to expand the donor pool as a result of increasing mortality rates among listed
patients.

1.3.1 Research Motivation
UNOS data shows that 10 percent of the waiting population dies before a liver is
available [14]. Unfortunately liver transplantation ranks among the most expensive
medical services and costs hundreds of thousands of dollars [16]. The existing system of
liver allocation gives more preference to patients living near donor, (i.e. more emphasis is
placed on geography than trying to ensure urgency). Only organs which are not suited
within an Organ Procurement Organization (OPO) is given out for regional allocation and
later if there is no match found in the region is offered nationally. There is very little
rationale explaining the reason behind this.
The existing system takes into account of medical factors including waiting time
and HLA level medical severity calculated using Model For End Stage Liver Disease
(MELD) score and blood compatibility [21]. Efficiency is more and more emphasized in
the existing policy and little effort is given to make the system equitable in terms of
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geography, race gender and others, As a result the system that fails to address the equity
issues associated.
The risk of death among women, Asians, Hispanics and children are more than
that of rest of the population due to a longer waiting time for transplant than foreign
nationals and repeat transplant patients [17]. There exists a wide disparity in waiting
times across different regional allocation of livers ranging from 31 days to 207 days [18]
[20].
The number of patients registered for transplant doesn’t match with the rapidly
growing mortality rate associated with shortage of organs. Procured livers remain
transplantable only for a limited period of time based in the Cold Ischemic Time (CIT)
normally ranging from 18 – 24 hours [19]. Two most important issues associated with
allocation delays and maximum utilization of this scarce life saving resource are 1)
Quality of match and 2) increase in rejection rate. About 10 to 15% of patients die while
waiting for transplantation. Due to the severe shortage of livers, an increase in the quality
of the allocation procedure and policy is critical for ESLD patients.

1.3.2 National Organ Transplant Act
The responsibility of the Organ Procurement and Transplantation Network
(OPTN), formed by the National Organ Transplant Act (NOTA) of 1984, ensures the
national registry of organ transplants is established with an emphasis on the development
of equitable and efficient organ allocation policies [22]. NOTA asserts that a proper
system to allocate donated organs for transplantation among transplant centers and
patients should be ranked according to established medical criteria. The Senate Labor and
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Human Resources Committee amended NOTA with the following: an equitable system is
necessary such that individuals throughout the country can have equal access to organ
transplantation when appropriate and necessary [22]. The allocation of transplantable
organs has been the subject of considerable debate throughout the transplant community
during the last decade [23]. A debate which reached congress in 1998 remains unsettled
since then.
The UNOS is responsible for managing the national organ donation and allocation
system. The current allocation procedure was approved for implementation on February
28, 2002 [14]. In the last six years there has been four changes in policy [24]. These
multiple changes highlight the challenge in forming a consensus on allocation policy.

1.3.3 Efficiency and Equity in Liver Allocation
The goal of a proper allocation policy is to identify a system which is equitable
and efficient. In an equitable system, each individual on a transplant waiting list has an
equal opportunity to receive a transplant subject to established medical and demographic
criteria. No discrimination or privilege for one patient over another based on region,
ethnicity etc. Efficiency implies the diminution of the wastage of donated livers available
for transplantation. Equity in our research is measured in terms of the difference over
efficiency outcomes.

1.4 Analytic Hierarchy Process
The Analytic Hierarchy Process (AHP) is capable of combining qualitative and
quantitative criterions in decision making processes. The AHP model is successful in
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practice and has numerous and diverse applications. AHP’s capability of handling
complex decision problems is well acknowledged. AHP can handle complex and poorly
defined problems which rigorous mathematical models display difficulty in solving. AHP
has the ability to handle mix qualitative and quantitative criteria within the same decision
framework. It also helps create a consensus of scenarios or situations by converting
qualitative decisions to quantitative data. AHP has the ability to handle both tangible and
intangible attributes, define the structure of a scenario through its inherent hierarchical
model and verify the consistency of end decisions

1.5 Research Contributions
This research aims to balance the trade-off between efficiency and equity in liver
transplantation, an issue that is heavily debated. This framework can also be used for
making similar policies addressing the efficiency and equity tradeoff. The AHP approach
is used to quantify the decision making process and build logics with complex decision
making criteria for policy selection. This research addresses the concerns regarding the
need for a change in allocation policy, which needs to reduce or eliminate inequity in
organ transplantation system.
The latest data from UNOS is used in our research. This research uses AHP
methodology for organ allocation. Even though numerous application of AHP can be
found in complex medical decision analysis process, as such none of the applications uses
the capability of AHP in selection and evaluation of organ allocation policies. Our
research aims to address the concerns in liver allocation policy by tying efficiency and
equity together, which previous researchers held separate.
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CHAPTER 2
LITERATURE REVIEW

2.1 Introduction
This chapter discusses the literature related to the research. In section 2.1 we will
introduce Analytic Hierarchy Process (AHP), describe several applications, and
summarize various solution techniques. In section 2.3 we will summarize previous
studies that apply AHP to medical decision making problems. In section 2.4 will discuss
previous decision making methodologies in the national liver allocation system. Finally,
section 2.5 will provide analysis on the previous studies addressing efficiency and equity
in liver allocation.

2.2 Analytic Hierarchy Process
AHP is a multi-criteria decision making tool that is flexible and used across wide
variety of disciplines. It helps analyze both quantitative and qualitative aspects of a
decision process. AHP was developed by Thomas L Saaty in 1970 [25]. An advantage of
AHP over other multi-criteria decision making methods is that the AHP can incorporate
tangible as well as intangible factors, especially when the subjective judgments of
different individuals constitute an important part of the decision process. The method is
widely used in varying areas such as politics, economics, sociology, and even in medicine
because of the following advantages: 1) this method can handle both quantitative and
qualitative data all at once; 2) this method uses the eigenvector and eigen-value property,
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which presents a computational advantage 3) a reduction in cognitive burden to decision
makers when comparing with other similar methods and 4) previous works have already
verified the advantages of this method with numerous case studies. AHP has broad
application areas including planning, resource allocation, conflict resolution and
optimization and selection of the best alternative [26]. This research uses the selection
approach of AHP: selecting the best alternative from a set of given feasible alternatives.
AHP utilizes a numeric scale to calibrate the measurement of quantitative as well as
qualitative performances (Table 2.1), the scale ranges from one to nine with one
corresponding to least favored and progressively moving up the scale to nine which
corresponds to very strongly favored.

Table 2.1 The Fundamental Scales (Saaty and Vargas, 2000)
Numerical Score

Definition

Explanation

1

Equal Importance

Two activities equally contributes to the objective

2

Weak

3

Moderate importance

Experience and judgment slightly favor one activity
over another

4

Moderate plus

5

Strong importance

Experience and judgment strongly

favor one

activity over another
6

Strong plus

7

Very strong or

An activity is favored very strongly over another; its

demonstrated importance

dominance demonstrated in practice

8

Very, very strong

9

Extreme importance

The evidence favoring one activity over another is
of the highest possible order of affirmation
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2.2.1 Methodology
AHP aids in formulating a multi-attribute decision problem in the form of a
decision tree, where each of the hierarchy level involves a variety of criteria. It can be
from a simple single level hierarchy to a multiple level (n) hierarchy. AHP addresses the
decision problem of choosing the best alternative by systematic and quantitative
comparison of different criteria using pair-wise comparison techniques. Mathematically,
it determine the weights of the comparison pairs Ci for i = 1 to n’ where n is the number
of criteria.
AHP exceeds the comparative judgment approach by relaxing the normality
assumption of parameters. In this research, AHP is used in this research to develop and
analyze trade off between conflicting outcomes in the course of structuring reciprocal
pair-wise comparison matrices.
AHP starts by breaking down the problem hierarchically; each level of the
hierarchy consists of a few manageable elements. These elements are further sorted to
another set of sub-elements. This process continues until all specific elements of the
problem are measured, which in turn represents the lowest level of the hierarchy.
Structuring the problem hierarchically reduces the complex nature of the problem and
helps identify the major components. It also helps us understand the problem in a better
manner and sort the trivial and non trivial elements.
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2.2.2 An Overview of AHP Applications
The AHP model has found numerous successful applications. An overview of
AHP in various areas is presented in Vaidya and Kumar (2004). These applications for
AHP include decision making in personal, social, manufacturing, politics, engineering,
education, government and health care applications. The authors reviews several
approaches used in AHP, selection, evaluation, priority, development, resource
allocation, decision making, forecasting, medicine [26].
In a review of the 150 top-tier journals, the most popular applications of AHP
falls either in the combination of engineering application and selection approach or social
application and selection approach. AHP has been used in many cases as a stand-alone
application however variations of AHP such as fuzzy AHP or a combination of AHP with
tools like linear programming, artificial networks and fuzzy set theory makes it more
versatile and expands the application areas. The application of AHP is also seen a
increasing trend as more and more top tier research publications like the European
Journal for Operations Research (EJOR) have special editions and annual symposium for
AHP being held due its increased application areas.
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Figure 2.1 AHP Themes

2.3 Selection Theme
Forman and Gass (2001) mention several AHP applications in selecting best
alternatives from a given set of multiple alternatives in a multi-criteria environment. The
application areas include product selection, vendor selection and policy decision. Their
paper talks about application of AHP in more than 50 research decision situations within
the Xerox Corporation; such as portfolio management, engineering design selection,
technology implementation, market segment prioritization and customer requirement
prioritizing [27]. Sharp (1987) discusses the application of AHP in their selection of
lowest cost haulers to handle the dispatches to reduce dispatch costs [29].
AHP has a significant role in group decision making, Dyer and Forman (2002)
state the benefits of using AHP in group decision making through decomposition,
comparative judgment and synthesis of priorities [30].
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2.4 AHP in Health-Care
AHP has been a powerful tool to health care decision makers. Many common
themes have been found in AHP aided decision making in the health care industry. This
literature review will mainly discuss the application of AHP in clinical and medical
decision evaluation. The problems mostly use the selection and decision making
approach of AHP [26]. Application of resource allocation and prioritization themes can
be found in a) medical staff decision making b) identifying alternative technologies to
purchase, c) assisting patients in their decision making process. AHP is not only capable
of analyzing economic and technical factors in the healthcare industry but also social and
human factors [31[32] [33]. Hariharan et. al (2005) presents an application of AHP for
measuring and comparing the global performance in quality of intensive care units [34].
Different approaches have been taken in health care decision making problems
using AHP, as demonstrated in the following two examples. Wu, Lin and Chen (2006)
apply AHP in optimal selection of locations for Taiwanese hospitals [35]. The model
addresses the burgeoning health care quality consciousness among Taiwanese residents
and improves scope of medical services considering a competitive advantage. Rosetti et
al (2001) address decision problem for hospital deliver systems that addresses economic
and technical performance as well as social human and environmental factors. The model
enables a better understanding of delivery and transportation requirements in medium and
large size hospitals [36].
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2.5 AHP in Medical Decision Making
Min et. al (1997) propose a model which helps medical clinics improve service
strategies in the competitive health care industry. Their research uses AHP for the
comparative evaluation of quality benchmarking in health care service improvement [37].
A recent development in technology and bioethics enables an increased participation
from patients in their own health care decision making, resulting in a shared decision
making model Singpurwalla et al (1999) [39].
Liberatore et. al, (2003) uses AHP to model a shared decision making among
patients and physicians for addressing the growing concern of prostate cancer in men.
The model also successfully captures the decision-counseling protocol for cancer
screening. The adaptability of AHP in modeling complex problems is emphasized to fit
the research. The paper describes the methodology in three steps of which the first is
identifying the alternatives available and personal criteria for evaluation. Secondly
determining how the alternatives achieve the personal criteria based on analysis thirdly to
determine the priority of the steps and finally deciding among alternatives. The study
emphasizes the lack of training needed for patients who are involved in decision making
and the addresses the necessity of more application of AHP to personal decision making
[39]. Applications of AHP in medical decision making and medical decision support can
be found [40 [41] [42].
Cook, Staschak and Green (1990) work on the equitable allocation of livers for
orthotropic transplantation they consider the major factors to logistics, tissue
compatibility, waiting time, financial and medical status. They rate the patients in terms
of main categories based on their rank in subcategories using pair-wise comparisons [33].
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They state that the system lacks formal evaluation and is based on the intuition of
individuals involved. While equity is heavily emphasized, efficiency of the
transplantation is poorly addressed. Equitable provision and healthcare financing is one
of the National Health Service’s (NHS) growing concerns since its inception (Sassi et al
2001). Awareness of widening health equities since the publication of Black report has
raised equity to a high rank among policy makers.

16

CHAPTER 3
PROBLEM STATEMENT AND METHODOLOGY

3.1 Introduction
Allocating available livers to necessary patients involves a lot of discretion.
Choosing an optimal liver allocation policy among a set of alternatives is a challenge
given the subjective nature of this problem. The decision maker may not be able to make
consistent decisions addressing the efficiency and equity in selecting policy. Decisions
involved in selecting the best policy must consider various outcomes of liver
transplantation including efficiency, equity and trade-offs between them [45]. This makes
the problem a Multi-Attribute Decision Making problem (MADM). AHP is a MADM
methodology which helps quantify the decision making process and gives decision
makers the ability to reach a valid consensus in decision making rather than depending
totally on their intuition [25].

3.2 Current Liver Allocation System
This section provides an overview of the existing liver allocation system.
Knowledge of the existing system will help in understanding the difficulty faced by
decision makers in allocating available livers to ESLD patients. UNOS operates the
national system for organ transplantation. It is responsible for managing and
administering the proper allocation of available organs for transplantation. The current
liver allocation system was implemented in February 28, 2002 [20]. The policy has been
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changed four times in the last six years [21]. Numerous changes in such a small duration
shows that there is a need for improvement in the liver allocation policy.

3.2.1 United Network for Organ Sharing
UNOS is responsible for every organ transplant performed in the United States.
UNOS supervises the organ donation and procurement via non-profit agencies called
Organ Procurement Organizations (OPO).

OPOs provide organ recovery services,

manage the clinical care of the donors, enter donor information into the UNOS computer
database to find a match and coordinate the organ recovery process to hospitals located
within designated geographical area in the U.S. OPO’s also promote organ donation in
their communities by sponsoring workshops and participating in community health fairs
and events [14].
The national UNOS membership is divided into 11 geographic regions, each
consisting of several OPOs. This regional configuration was developed to facilitate organ
allocation and to offer individuals the opportunity to identify concerns regarding
procurement, allocation, and transplantation of organs that are unique to their region.
The patients are divided in to two categories PELD and MELD based on the age.
PELD score is for patients under 18 years of age. In our research we are focused on the
adult liver allocation procedure. UNOS maintains a patient waiting list that is used to
determine the transplant candidates among the patients. When a liver becomes available,
the following factors are considered for its allocation: medical urgency of the patient,
patients OPO, patient region, patient score from clinical and medical urgency, and patient
waiting time (Figure 3.1).
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UNOS provides a framework of principles for making policy decisions about
organ allocation. Currently the existing systems follow a “sickest first” approach. Patients
with severe medical urgency will be offered the liver first [47].

Figure 3.1 Schematic Representation of Current Liver Allocation System

Figure 3.1 explains about the current liver allocation procedure. Every liver
available for transplant is first offered to those Status 1 patients located within the
harvesting OPO based in descending order of MELD score. If there are no suitable Status
1 matches within the harvesting OPO, the liver is then offered to Status 1 patients within
the harvesting region. If a match still has not been found, the liver is offered to all nonStatus 1 patients in the harvesting OPO in descending order of MELD score. The search
range is again broadened to the harvesting region if no suitable match has been found
within the harvesting OPO. If no suitable match exists in the harvesting region, then the
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liver is offered nationally to Status 1 patients followed by all other patients in descending
order of MELD score [14].

3.3 Liver Transplantation Issues
In the existing liver transplantation policy, more emphasis is given in the
geography of patient than balancing the equity issues associated with the model. A
harvested liver is first distributed according to medical condition and then by the
proximity towards the transplant OPO. This results in wide inconsistency as a patient’s
chance of living or dead is based on where they live than their medical urgency [20]. The
condition becomes worse when current policy allow people to list in more than one
geographical region, known as multiple listing. Many patients who are able to list in more
than one region stand a higher chance of obtaining a liver than people listed in only one
region [21].
Any organ allocation policy should satisfy at least the following three
performance goals: 1) identify and establish standardized criteria for measuring proper
medical scores for eligibility of transplant patients before adding to the waiting list, 2)
facilitate a fair comparison of patients across the waiting list. Geographical preference of
the patients should be widely reduced and more emphasis should be give to the equity
aspect [50]. A change in the increased emphasis on efficiency should be pushed by
regulations to encourage a move to a more equitable system.
There is less rationale in providing a liver to a severe End Stage Liver Disease
(ESLD) patient irrespective of the survival rate [20].

Two specific and somewhat

conflicting goals should be considered for decision making in transplantation: efficiency
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of the transplantation and equity in transplantation [22]. Which one should be given more
emphasis, fairness surely gives higher preference to equity, but utilization emphasizes on
higher efficiency. We shall balance the efficiency and equity of these conflicting
outcomes and reach a more desirable decision making policy.

3.4 Analytic Hierarchy Process
The AHP method by Saaty is based on two important theoretical principles: the
fundamental scale for ratio comparison, and the eigenvector and eigen value property
[25]. Saaty utilizes a fundamental scale ranging from one to nine. The scale has its origin
on the Weber-Fechner’s sensation (response) equation “Law of stimulus of measurable
magnitude” (i.e. M = a log s + b, a ≠ 0 ) where M denotes the sensation and s the stimulus)

(Fechner, 1966) [52] [53]. When making pair-wise comparisons, nearest integer
approximation from the fundamental scales of one to nine is being used. This scale has
been validated for effectiveness in many applications by numerous individuals through
the theoretical justification of what scale one must use in the comparison of
homogeneous elements (Saaty and Vargas, 2000) [54]. The upper limit of nine is adopted
following Miller (1956)’s “Magical number theory” [55]. Alternatives are compared
based on this fundamental scales in a pair-wise comparison fashion; then a decision
matrix is composed [55].

3.5 Illustrative Example

We are using an example to explain the AHP methodology. There is an age old
adage which says apples cannot be compared with oranges. Our objective is to choose the
best fruit from a set of alternatives, including apple, orange and grapes. These can have
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many criterions in common: color, quality, appearance, seediness, etc. We may prefer an
orange for color criteria but for appearance criteria an apple and for quality criteria
grapes. Strength of our preference for these characteristics may vary. Even though we
may be indifferent to some attributes there will be strong preference for some other
attributes which may vary across circumstances.
The challenge is to identify a set of alternatives which strongly fulfills the goal
which satisfies entire set of objectives. The decision making is concerned with weighing
alternatives through pair-wise comparison.

3.5.1 Decomposition and Development of Hierarchy Structure

The AHP methodology suggests the development of a hierarchical structure. The
formulation of a decision hierarchy is a critical step in AHP because it helps to
effectively frame a problem and simplify the analysis process. It also helps to decompose
the problem into inter-related decision element goals, attributes and alternatives. In our
specific example the hierarchy structure consists of a three-level hierarchy consisting of a
final objective goal, level of attributes through which these alternatives are being
evaluated including color, quality, appearance and seediness and
alternatives, apple orange or grape to chose from (Figure 3.2).
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final level of

Goal

BEST FRUIT

COLOR

QUALITY

APPEARANCE

SEEDINESS

Criteria

Alternatives
APPLE

ORANGE

GRAPES

Figure 3.2 Evolution of Hierarchy Model for Fruit Selection

3.5.2 Evaluation of Hierarchy

The second step in an AHP process is the evaluation of the hierarchy.
1) Identify the preference weights (judgments) by pair-wise comparison of the
decision elements.
2) Synthesize the preference weights to determine the most preferred alternative.

Let us consider the elements from C1 , to Cn of some level in hierarchy. The weights of
influence W1, to Wn are found on some element in the next level. We will determine the
pair-wise comparison matrix aij (i, j = 1, 2, n) which indicates the strength of Ci when
compared with Cj. The matrix of these numbers aij is denoted A, or
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a12
a13 a1n ⎤
⎡ 1
⎢1 / a12
1
a 23 a 2 n ⎥⎥
A =⎢
⎢1 / a13 1 / a 23
1
a 3n ⎥
⎢
⎥
⎣1 / a1n 1 / a 2 n 1 / a 3n 1 ⎦

(3.1)

The matrix can be also be denoted as aij = 1/ aji ,, that is the matrix A is reciprocal.
If at any level of hierarchy the attribute of Ci is of equal relative importance as Cj, then aij
= 1, aji = 1; In particular aii = 1 for all i. If our judgment is perfect in all comparisons then
aik = aij * ajk for all i,j,k, and we can call matrix A as a consistent matrix. In a consistent
matrix the comparisons are based on exact measurements and; If the weights W1, to Wn
are already known. Then
aij =

wi
(for i, j = 1, 2, …, n).
wj

(3.2)

thus
aij * ajk =

wi
wi wj
=
= aik
*
wj wk
wk

(3.3)

This leads to
aji =

Wj
1
1
=
=
Wi
aij
wi / Wj

(3.4)

Considering the matrix equation
A.x = y

(3.5)

Where x = ( x1 , . . . . . . .xn ) and y = ( y1 , . . . . . . .yn )
n

∑ a xi = y , (for i = 1, 2, …, n).
ij

i

j=1

This gives us
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(3.6)

aij *

wj
= 1, (for i, j = 1, 2, …,n).
wi

Consequently
n

∑a

ij

wj = nwi (for i = 1, 2, …, n).

j=1

Which is equivalent to
(3.7)

Aw = n w

where A is a consistent matrix. In general, small deviation in aij may lead to large
deviations both in Eigen value λmax and in Wi (for i = 1,2, to n). It necessitates the need
for stable solutions which satisfies the condition. The reciprocal matrix satisfies the
conditions and gives a more stable solution. When considering the reciprocal of the
matrix A which is represented as A', from the pair-wise comparisons, the solution can be
represented as
A'w' = n w'

(3.8)

Several approximation methods are available to identify the weights of the
comparison vector of which, the most recommended method geometric approximation is
utilized in this research. This method multiplies all the n elements in the pair-wise
comparison matrix and the resulting weights of corresponding alternatives normal the
results obtained by taking the nth root for matrix of n alternatives.
From our example consider the priority vector matrix

3
5
⎡ 1
⎢1 / 3 1
5
A' = ⎢
⎢1 / 5 1 / 5 1
⎢
⎣1 / 7 1 / 9 1 / 4

7⎤
9⎥⎥
4⎥
⎥
1⎦
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The multiplication of each row results in (105, 45/3, 4/25, and 1/252)
respectively. Each value is raised to the power 1/n. In this example n = 4. The result is
represented by priority vector p
⎡ 105 (1 / 4) ⎤ ⎡ 3.201 ⎤
⎢
⎥ ⎢
⎥
45 / 3(1 / 4) ⎥ ⎢ 1.968 ⎥
⎢
=
P=
⎢ 4 / 25 (1 / 4) ⎥ ⎢ 0.632 ⎥
⎢
⎢
⎥
(1 / 4 ) ⎥
⎢⎣1 / 252
⎥⎦ ⎣ 0.251⎦

These values are normalized using a linear normalization method. The sum of the
all elements of column vector P is calculated, each element is then divided by that sum of
elements. In our example, the sum of elements is found to be around 6.052. After
normalization, the vector of weights is given by w.

⎡ 3.201 6.052 ⎤ ⎡0.5289
⎢1.968 6.052 ⎥ ⎢
⎥ = ⎢ 0.3251
w =⎢
⎢0.632 6.052⎥ ⎢0.1044
⎢
⎥ ⎢
⎣ 0.251 6.052 ⎦ ⎢⎣0.0414

⎤
⎥
⎥
⎥
⎥
⎦⎥

3.5.3 Consistency Index and Consistency Ratio

Consistency of the decision is a big issue to be addressed in any decision making
methodology. The matrix A (aij) is said to be consistent only if the principal eigen value
λmax is equal to or close to the order of the matrix (n). The sum of the eigen values of a
matrix is equal to its trace which is also equal to n.
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The human involvement of AHP makes it difficult for any one to give the precise
values of the pair-wise comparison ratio

wi
, rather only an estimate. Therefore, Saaty
wj

replaces the equation Aw = nw with Aw = λmax w. where λmax is the largest or principal
eigen value of matrix A. Saaty defines the difference between λmax and n as a Consistency
Index (CI).

CI is calculated by CI =

λmax − n
n −1

(3.9)

The consistency index of randomly generated reciprocal matrix for the ratio scale
1 to 9, with reciprocals forced is called as Random Index (RI). At Oak Ridge National
Laboratory, Saaty generated an average random index (RI) for matrices of order 1-15
using a sample size of 100. RI increases as the order of the matrix increases and is shown
in the following table as the sample size was only 100 and statistical fluctuation of
indexes from one order to the other (Table 3.2).

Table 3.1 Average Random Index (Oakridge National Laboratory)
N

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

RI

0.00

0.00

0.58

0.90

1.12

1.24

1.32

1.41

1.45

1.49

1.51

1.48

1.56

1.57

1.59

The ratio of C.I to average R.I for matrix of the same order is defined as Consistency
Ratio (C.R).
C.R = C.I / R.I

(3.10)
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Lower the consistency ratio will increase the consistency of the decision. Saaty
recommends using matrices of consistency ratios less than 0.1. If the consistency ratio is
greater than 0.1 such a matrix should be eliminated to calculate the weight so that the
decision made is more rational. Thus AHP methods use a combination of C.R and
powerful pair-wise comparison to resolve irrational humanistic responses.
wi
(for i, j = 1, 2, …, n). We use judgments which are quantified,
wj

Ideally, aij =

and all the allowances must be integrated. Deviations in the ratio aij and the number n,
now denoted by λmax, leads to λmax
wi =

1
λmax

n

∑a w
ij

j

i = 1, 2, …, n

(3.11)

j=1

A small deviation in aij can lead to a very large deviation in final weights. The
consistency in decision should be maintained throughout for accurate measurement of the
selection criteria.

3.6 Synthesis of Priorities

Once we have obtained weights of criteria, the next step is to prioritize the
alternatives based on the criteria. For each criterion the alternatives are prioritized based
on the decision matrix and priorities are obtained.
Pair wise comparison of criterion color is shown as follows
⎡.23076⎤
⎡ 1 3 1 / 3⎤
⎢
⎥
A' = ⎢1 / 3 1 1 / 9⎥ W' = ⎢⎢ .0796 ⎥⎥
⎢⎣ .6923 ⎥⎦
⎢⎣ 3 9 1 ⎥⎦

The matrix and the weights based on one of the criterion color as shown in the
above equation. The weight is obtained via the method previously mentioned. Similarly
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we can obtain the weights for other criteria including quality appearance and seediness
(Table 3.3).

Table 3.2 Weights Among Alternatives With Respect to Criteria

Evaluation

Color

Quality

Appearance

Seediness

Weights

0.164798

0.185184

0.437111

0.212907

Apple

0.230769

0.142857

0.177276

0.0704176

Orange

0.076923

0.714286

0.0852256

0.751405

Grapes

0.692308

0.142857

0.737498

0.178178

3.7 Overall Priority for Final Selection

Finally, the priority weights of each alternative can be calculated by weights per
alternative multiplied by weights of the corresponding criterion. The highest score of the
decision matrix implies the best choice of fruit. Synthesizing the priorities will give us
the weights of the criteria and the priorities of the alternatives based on each individual
criterion. Now we have to obtain the overall priority ranks which will help us in making
the decision.
For obtaining the overall ranking of alternatives we multiply the corresponding
alternatives with the weights of the criterion weights.
Ranking = Priorities × Weights of Criteria
The weight of alternative apple based on the criterion color is obtained by

Weight of apple based on color = 0.230769 × 0.16472 = 0.038030
Similarly weights of other alternatives are also obtained by sum product
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(3.12)

Table 3.3 Sum Product of Matrix
SUM
PRODUCT

Color

Quality

Appearance

Seediness

Results

Apple

0.03803

0.0264

0.0774892

0.014992

0.15696

Orange

0.012676

0.1322

0.037253

0.159979

0.34218

Grapes

0.11409

0.0264

0.3223684

0.037935

0.50084

3.8 Results

According to the decision matrix final scores, grapes are the most preferred due to
its high priority weight, Orange is the next recommended alternative. Through the
illustration of this AHP model, it is found that the fruit selection problem can be solved in
a structural and simple manner without involving much complexity. The sensitivity of
each fruit with respect to the attributes and main criteria also can be obtained. The final
priority weights of each fruit can be seen in Figure 3.3. The step by step computations
and comparison matrices of all the attributes are shown. The important results are also
shown in Figure 3.3.

0.6
0.5
0.4
Apple
0.3

Orange
Grapes

0.2
0.1
0
Color

Quality

Appearance

Seediness

Global Evaluation

Figure 3.3 Final Priority Weights Alternatives by Criterion
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The final priority weights of different criteria shows that the appearance of the
fruit carries the highest priority and it is followed by seediness, quality and color,
respectively. The factors that contribute most in fruit selection are appearance and
seediness.
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CHAPTER 4
MODEL DEVELOPMENT

4.1 Introduction

This chapter discusses decision making involved in finding a trade-off between
efficiency and equity outcomes which were modeled in a Multi-Criteria Decision
Analysis framework using Analytic Hierarchy Process. Additionally, important decision
criteria related to efficiency and equity involved in deciding the best policy are detailed.
The criteria discussed include average MELD score, waiting time, racial and geographic
equity which require considerable amounts of attention. We attempt to generalize the
model for all organ transplantation including liver, kidney, and tissues etc.

4.2 AHP Framework

Balancing efficiency and equity in U.S. liver transplantation can be modeled as a
multi-criterion decision problem which includes both qualitative and quantitative factors.
Reaching a consensus in selecting a policy is more complex when there are conflicting
attributes involved. AHP based methodology will be discussed to tackle the different
necessary but conflicting criteria. In our research criterion like efficiency and equity
including the sub criterions involved in the selection of alternative policy based on
existing liver transplantation scenario. In this research AHP is used to identify a
consensus in which how much a system should be balanced in terms of efficiency and
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equity outcomes. This research concentrates on a widely divided category of organ
transplant’s outcomes; i.e. efficiency and equity.

The aim of the National Organ

Transplant Act (NOTA) is to develop a policy which is efficient and equitable.
Categorized outcomes are as shown in (Table 4.1). The table comprises some of the
major outcomes which, we believe, affect an efficient and equitable distribution of
harvested organs.

Table 4.1 Classification of Efficiency and Equity Outcomes

Efficiency

Equity

Average Cold Ischemic Time (Hours)
No. of Previous Transplants
Age in Years at Time Of Listing
Recipient Length of Stay Post Transplant
Recipient Died (1=Dead,0=Alive)
Cold Ischemic Time (Hours)
No. of Days on Liver Waiting List
Average MELD Score
Age In Years At Time Of Listing

Race
Ethnicity Category
Gender
State of Residency at Registration

Recipient Length of Stay From Transplant
to Discharge
Recipient Days Between Previous And
Current Transplant
Allocation Type:
Local/Regional/National/Foreign

We categorize the measurable outcomes into two main subsets: Efficiency and
Equity. In the preliminary step for finding the optimal policy we break down the decision
problem into further criteria. These criteria will aid in building the hierarchy model, thus
facilitating the easy understanding of the problem and easing application of AHP
methodology.
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4.3 Selection Criteria for Liver Transplantation

Most decision makers cannot simultaneously handle more than 7 to 9 factors
when making a decision involving alternatives that have multiple attributes. It is
necessary to break down complex problems into more manageable sub problems which
help decision making. There is a large number of contributing but conflicting factors
simultaneously affecting the process of reaching a decision. An orderly sequence of steps
should be required whereby a complex problem, is broken down into to sub-problems
reducing complexity and produces an easy analysis.
Liver transplantation has four level of hierarchy. The following sections discuss
the different decision criteria, attributes and the decision alternatives. The objective is to
select a best liver allocation policy which balances efficiency and equity for the U.S. liver
transplantation system. Application of common criteria to all alternative policies makes
pair-wise comparisons possible.
The criteria which are considered are:
1. Efficiency
2. Equity

4.4 Liver Transplantation Outcomes

Liver transplantation outcomes are divided into efficiency and equity outcomes.
Our research focuses on efficiency and equity outcomes of the existing model for liver
allocation. Efficiency refers to the utilitarian view towards the systems and intends to
make the existing system efficiency oriented. In the equity oriented approach, the
egalitarian view argues for the equity of the system in all terms including gender, race,
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geography, etc. It is a challenge to develop a decision to process that is capable of
balancing efficiency and equity amongst large number of alternatives.

4.4.1 Efficiency Outcomes

The efficiency criterion is an important criterion in assessing the policy because it
can determine the effectiveness of the system in terms of utilization of scarce resources.
A good policy cannot be possible without maximum utilization of the available
transplantable livers. Considering a high rejection of more than 45%, maximum
utilization of transplantable livers should have a major influence [57].
While most of the medical factors including medical urgency, waiting time and
age have been taken in consideration some issues are not properly addressed; some of
the major factors (attributes) affecting this criterion can be stated as follows

4.4.1.1 Average MELD/ PELD Score

Efficiency of the system is attributed to the scoring model for calculating the
severity of disease. The MELD score reflects the patient's risk of dying while waiting for
a liver transplant based on clinical tests. . The MELD and PELD scores range from 6 to
40 and are based on objective and verifiable medical data. The MELD score is used for
adults, while the PELD score is used for patients who are less than 12 years of age. The
higher the MELD or PELD score, the greater the risk of dying from liver disease
The MELD score calculation uses:
•
•
•

Serum Creatinine (mg/dl)*
Bilirubin (mg/dl)
INR
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MELD Formula
MELD Score = 0.957 x Loge (creatinine mg/dL)
+ 0.378 x Loge (bilirubin mg/dL)
+ 1.120 x Loge (INR)
+ 0.643
Multiply the score by 10 and round to the nearest whole number.
The PELD score calculation uses:
•
•
•
•
•

Albumin (g/dl)
Bilirubin (mg/dl)
INR
Growth failure (based on gender, height and weight)
Age at listing

PELD Formula
PELD Score = 0.480 x Loge (bilirubin mg/dL)
+ 1.857 x Loge (INR) - 0.687 x Loge (albumin g/dL)
+ 0.436 if patient is less than 1 year old
+0.667 if the patient has growth failure
Multiply the score by 10 and round to the nearest whole number.
The likelihood of a critically ill person receiving a liver is higher than that of
patient who has a higher recovery chance. In the current scoring system, the median wait
time for re-transplant candidates is less than that of new transplant candidates. A
factorization of the score can be done based on transplant history. One of the primary
efficacy outcome is survival rate of patients after transplantation. Additionally, the
quality adjusted life years is another major outcome. Length of time in the waiting list
and quality of the liver obtained also attribute a lot towards the efficiency issues. Average
MELD score, length of hospitalization, rejection rate are secondary factors for deciding
the efficiency of a transplant.

36

4.4.1.2 Average Waiting Time

The length of time spent on the waiting list is another major attribute for the
efficiency of the system. For a more efficient system it is necessary that the average wait
time be reduced. This is a major factor in the measuring MELD scores. The wait time
determines the priority when there is a tie amongst patients of similar MELD or PELD
scores.

4.4.1.3 Acceptance Rate

Higher acceptance rate is directly related to the efficiency of the policy. It is
necessary for any alternative policy to have a very low rejection rate. There is a wide gap
between the available livers for transplantation and number of patients in the waiting list.
Liver transplantation is very expensive and costs hundreds of thousands of dollars. A
higher acceptance rate can substantiate the high cost involved with liver transplantation
and associated costlier post transplant medication.

4.4.2 Equity Outcomes

Equity of the liver allocation system should be viewed as equal as efficiency. The
measurement of equity contributes toward the fairness of a policy. Numerous criteria
which we can measure equity; are blood group, race, insurance, health conditions,
ethnicity, transplant OPO etc, as such important for any policy to be fair so that no policy
should be biased on things beyond their control. Our research considers, what we think, a
major contribution toward the equitable allocation via as geography, race and gender. We
consider the measurements as we view their inclusion as a means to create a more
equitable policy. Equity outcomes in this research are measured in terms of the difference
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in scores of specific efficiency outcomes over patient. For example The difference in the
MELD score across Hispanics Asians, Whites and African Americans.

4.4.2.1 Geographical Equity

Geographical equity is one of the major contributions toward the fairness of liver
allocation policies. The regional variability in wait time has prompted vigorous debate on
organ allocation policy. Certain parts of the nation failed to benefit from the regional bias
of current liver allocation policy. It is necessary for an ideal policy to reduce the regional
variability in allocation of livers.

4.4.2.2 Gender Equity

There is a wide disparity in the post transplant survival rate and acceptability of
organs based on the male and female. Any ideal policy should be able to recognize and
reduce this disparity to its bare minimum while maintaining an acceptable efficiency
level.

4.4.2.3 Racial Equity

Another major equity criterion measured is race. No policy should disadvantage
anyone for belonging to a certain race. Even though the current system does not explicitly
account for racial consideration, it is observed that there is a high racial disparity in the
number of transplants as well as the waiting time for people belonging to a particular
race. Any system should be fair in such a way that the difference among the race in terms
of efficiency attributes should be minimized or negligible.
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For all the major equity criteria and corresponding sub criteria, pair wise
comparisons are done in terms of the difference in the efficiency attributes. For example
if we consider the geographical equity criterion we will measure the difference in average
wait time across the different regions based on the national average. Similarly pair wise
comparison will be done for other criteria to obtain a quantitative justification in
determining priorities among the criteria.

4.5 Hierarchy Model

Policy
Selection

Equity

Efficiency

Average MELD score

Average
Waiting time

Acceptance
Rate
Asian

Race

Gender

Hispanic

Afro-American

Difference in Meld Score

Policy A

Policy B

Difference in waiting time

Policy x

Figure 4.1 Evolution of AHP Model for Balancing Efficiency and Equity
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Geography

4.6 Discussion of Methodology and Application

The problem discussed is the U.S. Liver transplantation and allocation policy;
searching for the best policy for balancing efficiency and equity. The research takes into
account the majority of possible criteria which can affect the decision maker. A detailed
discussion on every criterion, sub criterions, attributes and alternative policy has been
presented. Two critical criteria have been identified. The methodology has been used
further to select the numerous attributes (or sub-criteria) with for evaluating among
alternative policies.
The following steps have been considered to form the hierarchy:
(1) Define the issues considering the U.S. liver transplantation.
(2) Identify the overall objective of policy selection.
(3) Identify the criteria and attributes that must be satisfied to fulfill the overall
objectives.
(4) Identify decision alternatives or outcomes.
(5) Structure the hierarchy placing the objective at first level, criteria at second
level, attributes at third level, and decision alternatives at fourth level.
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CHAPTER 5
DATA ANALYSIS AND RESULTS

5.1 Introduction

In this chapter we will discuss about the sources of data, data extraction methods,
variables for analysis, simulation models, and data analysis software.

5.2 UNOS Data

The UNOS operates the national system for organ transplantation. As mandated
by policy, all transplanting institutions must report certain information for each transplant
performed. The UNOS liver committee selects the relevant set of variables to be report,
which are collected on standardized forms made available by UNOS. UNOS makes the
information publicly available in electronic format.
Two sets of latest data requested from UNOS.
1. Patient registration data
2. Patient follow-up data

5.2.1 Patient Registration Data

This data is provided as a SAS cport file. A cport file is a sequential file
containing one or more data sets or catalogs in SAS format. "Transport format" is a
format understood by all versions of SAS in all systems. The data contains waiting list /
transplant files. UNOS Standard Transplant Analysis and Research (STAR) files for liver
registrations and transplants were obtained. The transplant STAR file from UNOS
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contains information on all waiting list registrations and transplants of livers that have
been listed or performed in the U.S. and reported to the OPTN since October 1, 1987.
The data includes both deceased and living-donor transplants. There is one record per
waiting list registration/transplant event. Each record includes the most recent follow-up
information (including patient and graft survival) reported to the OPTN as of June 2006.
The patient information dataset consists of 142,873 records and 418 variables. These
variables are further classified into post transplant clinical information, pre-transplant
clinical Information, candidate information, donor information, waiting list data, etc.

5.2.2 Patient Follow-Up Data

The follow-up STAR file contains one record for each pre-transplant
measurement. There are multiple records per transplant for most cases. For instance, if a
patient was transplanted in January 1998, the graft has not failed, and the patient has not
been reported lost to follow-up database, we have many follow-up records with the same
transplant identification number i.e. transplant id. Follow up records for 6 month, 1 year,
2 year, 3 year, 4 year, 5 year, and 6 year etc can be obtained for each patient. The
variable for linking the follow-up data to the transplant STAR file is TRR_ID. The
number of record of patient ranges from one record to more than hundred records per
patient based on number of visits or tests conducted. The patient follow up dataset
consists of 675,279 records and 20 variables. Most of the variables are from the waiting
list category.
5.3 Statistical Analysis System (SAS)
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The SAS system is an integrated system of software products provided by the
SAS Institute that enables programmers to perform data analysis. In this research latest
version of SAS 9.1.3 (released on April 2006) licensed to University of South Florida is
used.

5.4 Data Patterns and Simulation Model

The main objectives of data analysis are to understand the system and to obtain
the inputs for a discrete-event liver transplantation simulation model. The simulation
model is intended to replicate the real life system. Patient’s cumulative distribution can
be obtained by using their MELD scores as input from the patient registration dataset.
This data was extracted from corresponding SAS dataset by avoiding the duplicates and
based on the year of focus. Appendix A presents the sas program to determine the
variables for extraction and the procedure for extracting the data. The different outcome
categories and configurations based the data input comprise the input for the simulation
model that will be described later in the chapter.

5.5 Extraction Procedures and SAS Data Sets

The SAS software package was used to extract the data from the database. SAS
file Extract1.sas is presented in Appendix A and was used as the master program that aids
in identifying the variables needed from each data file. These variables will be described
in more detail in the next section. Figure 5.1 illustrates the complete procedure used in
extracting all data in tables.
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Figure 5.1 SAS Data Extraction Flow Chart

The hexagonal blocks represents the processing steps, the square blocks represent
the data sets and tabulated results. The purpose of the PROC (Procedural) step is to
perform operations on data obtained from data step. Finally, the results of the analysis
were processed using Excel.
The analyzed data serve as input to the simulation model. The simulation model is
a clinically based, discrete event simulation model of ESLD in the United States. The
model is used for policy evaluation. It used input clinical data obtained from the analysis.
The model is used to generate outcomes. The outcomes are evaluated based on expert’s
opinion to obtain the weights of the evaluation criteria. Impacts on changes in policy to
various outcomes can be measured in this model.

5.5.1 Organ Procurement Organizations (OPO)

Each OPO considered is classified either as a transplant OPO or a donor OPO
depending on its functionality. For this research it is necessary to fix the number of
transplant and donor OPOs. We obtained all the distinct OPOs in use at any given time
starting from its inception. We are able to identify 87 donor OPOs and 57 transplant
OPOs. These are the variables that we obtained from the dataset:
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CTR_OPO --Transplant OPO.
OPO_CTR -- Donor OPO.
The dataset obtained is displayed in appendix B.

5.5.2 Regions and Transplant OPOs

The entire UNOS is divided into 11 regions for geographical allocation and
administrative purposes. Each OPO belongs to certain region based on the proximity.
Each region consists of multiple OPOs. It is necessary to find the regional allocation of
OPOs for all the identified transplant and donor OPOs. This information will be used to
evaluate regional equity. We classified the two major categories of OPOs to their
respectable regions.
Variables used from the dataset
Region – Region which an OPO belongs to.
CTR_OPO --Transplant OPO.
OPO_CTR -- Donor OPO.
We are able to classify all OPOs into different regions based on the analysis and
the result will be obtained from appendix C.

5.5.3 Discrete Distributions

This analysis provides the patient arrival rate for the simulation model. We fixed
the number of transplant OPOs as 57 for the research purpose. For 142,873 patient’s
information which we obtained the patients transplant OPOs, a discrete distribution based
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on these OPOs was obtained. There is wide disparity in the number of transplants.
Patients from New York and California nearly attributes to the 15% of all the transplants.

5.5.4 Cold Ischemic Time

Cold Ischemic time is a major factor that determines the quality of transplant livers.
Preservation methods are available for storing livers without much deterioration in
quality for at least 12 hours [58]. We conducted this analysis by finding the distance
between the Donor and Transplant OPOs and the cold ischemic time of patients for that
transplant. We sorted the entire database based on the distance between the transplant
center and the mean cold ischemic time is extracted. Few transplants have taken place
when the donor and transplant OPOs are more than 2500 miles. For close analysis the
OPOs are further subdivided to the distance of 100 miles for distance less than 2500
miles. For distance less than 500 miles we further divided the distance into sub categories
of 50 miles. A normal distribution was fitted with 95% confidence interval.

5.6 Data Variables and Hierarchy

A hierarchy model helps decompose the problem in several stages. The aim of the
model is to obtain a policy among the alternative policy recommendations. How do we
test the alternative policies? Alternative policies can be tested for efficiency and equity
based on certain outcomes of the policy that are obtained from the simulation model.
The model generates waiting list times and survival rates, graft failure, and retransplant rates under the current UNOS liver allocation strategy, which emphasizes the
severity of disease and incorporates the MELD risk score. A set of outcomes for various
policies being obtained from the simulation model.
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The outcomes of the simulation model were reviewed by experts. These Experts
include transplant policy makers, physicians, and or focus groups among patients. They
suggest the importance of the outcomes. Values from the outcomes obtained from the
survey can be used to calculate the weights. This will help prioritize the impact of
allocation policy and the contribution of each policy towards efficiency and equity of the
model.

5.7 Merge – Registration and Follow-Up Data

The main objective of this part of the analysis is to create a library to store the
extracted data and create a working data set from each of the two distinct data sets. As
mentioned above, the database includes two datasets files, the patient registration data
and patient follow-up dataset, necessary variables from each file were chosen from the
data sets and finally the files were merged by patient id number (wl_id in the database).
Merging was done to obtain the patient file information where the necessary variables for
analysis were found in two different datasets
The Extract1.sas was updated in every analysis. Specific data sets are extracted
from the database based on certain parameters for example based on year, MELD score,
PELD score etc. In order to extract a specific set of data in a tabular format, smaller SAS
programs were created. Sample sas program (Subextract.sas) is presented in Appendix A.
This program extracts the patient id, initial and final MELD scores, Dates of visit to
transplant center etc from the follow up file.
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CHAPTER 6
CONCLUSIONS AND FUTURE WORK

6.1 Concluding Remarks

In this research we studied efficiency and equity, two major conflicting factors of
the United States liver transplantation. This research aims to find a policy which balances
efficiency and equity of current liver transplantation. The problem was modeled using
Analytic Hierarchy Process.
This research classifies the outcomes of liver transplantation into two major
criteria: efficiency and equity. The majority of the attributes contributing towards these
criteria have been identified. Some of the attributes which contribute to efficiency are
average MELD score, length of wait time, and patient rankings. Major attributes that
contributed toward equity included geographical location, race and gender. The AHP
approach helps quantify the decision making process to build logics into a complex
decision evaluation process that involves policy selection. The proposed model is capable
of obtaining the weights of these defined attributes with the goal of establishing the major
criteria regarding efficiency and equity.
Results from our data analysis that used the latest UNOS data, serve as inputs for
a simulation model. The simulation model is capable of evaluating different strategies for
liver allocation; the resulting outcomes can be quantified for decision making purposed
using the proposed model. The AHP methodology helps decision makers reach a
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consensus in a quantifiable method whereas previous methods heavily rely on intuition.
This research studies the deficiencies of the current liver transplantation policy
and proposes alternative strategies that may help policy makers search for a better policy
to balance efficiency and equity. Measurement of alternative policies can be done using
the simulation model. The proposed model is flexible enough to accept future changes in
the U.S. liver transplantation policy.

6.2 Future Extensions

Some of the extensions that can be made for this research are:
1. Selection of proposed policy can be done through AHP model.
2. Different perspectives (policy makers or patients) towards the allocation
policies can be studied.
3. The optimality criterion can be included for future research.

49

REFERENCES

[1] Kenneth D. Kochanek, M.A., and Betty L. Smith, B.S. Ed. Deaths: Preliminary data
for 2002. National vital statistics reports; Volume 52 Issue 13, Division of Vital
Statistics. 2004.
[2] UC Atlas of Global Inequality available from http://ucatlas.ucsc.edu/spend.php
accessed on October 2 2006.
[3] OECD Health Data 2005: How Does the United States Compare
www.oecd.org/health/healthdata accessed on October 2 2006.
[4] Center for Medicare and Medicaid Services, 2006. Available from
http://cms.hhs.gov/ information and data accessed on October 2, 2006.
[5] National Health Care Expenditures Projections: 2005-2015 February 22 2005
available from http://www.openminds.com/indres/CMSprojections2006.htm
information and data accessed on October 2, 2006.
[6] World Health Report 2000. Available at: http://www.who.int/whr/2001/
archives/2000/en/index.htm. Accessed October 2, 2006.
[7] Borger, C Health Spending Projections Through 2015: Changes on the Horizon,
Health Affairs Web Exclusive W61: 22 February 2006.
[8] California Health Care Foundation. Health Care Costs 101 -- 2005. 02 March 2005.
[9] Business communication company Inc., 25 Van Zant Street, Norwalk, CT 06855
available from http://bccresearch.com/editors/RB-103R.html Accessed August 13,
2006.
[10] The official U.S. Government web site for organ and tissue donation and
transplantation, www.organdonor.gov, Accessed August 13, 2006.
[11] National Kidney Foundation. 25 Facts about Organ Donation and Transplantation
http://www.kidney.org/news/newsroom/fsitem.cfm?id=30 Accessed August 13,
2006.
[12] IOM. Organ Procurement and Transplantation. National Academy Press,
Washington, D. C., 1999. Available from Institute of Medicine (IOM) website,
http://www.iom.edu/.

50

[13] Organ procurement and transplantation network. www.optn.org Data 2000 – 2001.
[14] UNOS, 2006. Available from http://www.unos.org, information and data accessed
on August 16, 2006.
[15] Organ procurement and transplantation network [Internet]. Richmond (VA): United
Network for Organ Sharing; c2003 [modified 2005 Nov 18; cited 2005 Nov 23].
Available from: http:// www.optn.org/latestData/step2.asp?.
[16] Gilbert JR, Pascual M, Schoenfeld DA, et al. Evolving trends in liver
transplantation: an outcome and charge analysis. Transplantation. 1999;67(2):24653.
[17] Belle SH, Beringer KC, Detre KM. An update on liver transplantation in the United
States: recipient characteristics and outcome. In: Terasaki CA, ed. Clinical
transplants. Los Angeles: UCLA Tissue Typing Laboratory, 1995:19-33.
[18] Klassen AC, Klassen DK, Brookmeyer R, Frank RG, Marconi K. Factors
influencing waiting time and successful receipt of cadaveric liver transplant in the
United States, 1990 to 1992. Med Care 1998;36:281-294.
[19] Furukawa H, Todo S, Imventarza O, et al. Effect of cold ischemia time on the early
outcome of human hepatic allografts preserved with UW solution. Transplantation
1991;51:1000-1004.
[20] Padbury RT, Attard A, Mirza DF, et al. Extended preservation of the liver with UW
solution -- is it justifiable? Transplantation 1994;27:1490-1493.
[21] P. A. Ubel and A. L. Caplan. Geographic favoritism in liver transplantation–
unfortunate or unfair? New England Journal of Medicine, 339(18):1322–1325, 1998.
[22] Siminoff LA, Arnold RM, Caplan AL, Virnig BA, Seltzer DL. Public policy
governing organ and tissue procurement in the United States: results from the
National Organ and Tissue Procurement Study. Ann Intern Med 1995;123:10-17.
[22] National Organ Transplant Act: Public Law 98-507.U.S. Statut Large.1984;98:2339
48.
[23] Steward A. Jersey lawmakers vow to fight changes in organ transplant rules. The
Star Ledger. May 5, 1998:28.
[24] Government Accounting Office, 2003. Available from http://www.gao.gov/ special.
pubs/organ/chapter2.pdf, information and data accessed on January 21, 2003.
[25] Saaty, Thomas L. (1980). The Analytic Hierarchy Process: Planning, Priority
Setting, Resource Allocation. McGraw-Hill. New York.

51

[26] Vaidya, O. S., and Kumar, S., 2006, “Analytic hierarchy process: an overview of
applications” European Journal of Operational Research, 169, 1-29.
[27] Triantaphyllou, Evangelos (2000). Multi-criteria Decision Making Methods: A
Comparative Study. Kluwer Academic Publishers. Boston.
[28] Ernest H. Forman; Saul I. Gass The Analytic Hierarchy Process: An Exposition (in
OR Chronicle) Operations Research, Vol. 49, No. 4. (Jul. - Aug., 2001), pp. 469486.
[29] J. A. Sharp Haulier Selection-An Application of the Analytic Hierarchy Process (in
Case-Oriented Papers) The Journal of the Operational Research Society, Vol. 38,
No. 4. (Apr., 1987), pp. 319-328.
[30] R.F. Dyer and E.H. Forman, Group decision support with AHP, Decision Support
Systems 8 (1992) (2), pp. 99–124.
[31] S.L. Ahire and D.S. Rana, Selection of TQM pilot projects using an MCDM
approach, International Journal of Quality & Reliability Management 12 (1995) (1),
pp. 61–81.
[32] Kyung S Park and Chee Hwan Lim A structured methodology for comparative
evaluation of user interface designs using usability criteria and
measures International Journal of Industrial Ergonomics, Volume 23, Issues 5-6, 20
March 1999, Pages 379-389.
[33] D.R. Cook et al., Equitable allocation of levers for orthotopic transplantation: An
application of AHP, European Journal of Operational Research 48 (1990) (1), pp.
49–56.
[34] S. Hariharan, P.K. Dey and D.R. Chen et al., Application of analytic hierarchy
process for measuring and comparing the global performance of intensive care units,
J Crit Care 20 (2005), pp. 117–124.
[35]Cheng-Ru Wu, Chin-Tsai Lin and Huang-Chu Chen Optimal selection of location for
Taiwanese hospitals to ensure a competitive advantage by using the analytic
hierarchy process and sensitivity analysis.
[36] M.D. Rossetti and F. Selandari, Multi-objective analysis of hospital delivery
systems, Computers and Industrial Engineering 41 (2001) (3), pp. 309–333.
[37] Hokey Min, Amitava Mitra and Sharon Oswald , Competitive benchmarking of
health care quality using the analytic hierarchy process: an example from Korean
cancer Clinics Socio-Economic Planning Sciences, Volume 31, Issue 2, June 1997,
Pages 147-159.

52

[38] N. Singpurwalla, E. Forman and D. Zalkind, Promoting shared health care decision
making using the analytic hierarchy process, Socio-Economic Planning Sciences 33
(1999) (4), pp. 277–299
[39] Matthew J. Liberatore, Ronald E. Myers, Robert L. Nydick, Michael Steinberg, Earl
R. Brown, Roy Gay, Thomas Powell and Roberta Lee Powell, Decision counseling
for men considering prostate cancer screening Computers & Operations Research,
Volume 30, Issue 10, September 2003, Pages 1421-1434.
[40] Dolan, J. G., 1989, “Medical decision making using the analytic hierarchy process:
choice of initial antimicrobial therapy for acute pyelonephritis” Medical Decision
Making, 9 (1), 51-56.
[41] Dolan, J. G., 1995, “Are patients capable of using the analytic hierarchy process and
willing to use it to make clinical decisions?” Medical Decision Making, 15 (1), 7680.
[42] Dolan, J. G., and Bordley, D. R., 1993, “Involving patients in complex decision
about their care: an approach using analytic hierarchy process” Journal of General
Internal Medicine, 8 (4), 204-209.
[43] Franco Sassi Setting priorities for the evaluation of health interventions: when theory
does not meet practice Health Policy, Volume 63, Issue 2, February 2003, Pages
141-154.
[44] Elliot B. Sloane, Matthew J. Liberatore, Robert L. Nydick, Wenhong Luo and Q. B.
Chung Using the analytic hierarchy process as a clinical engineering tool to facilitate
an iterative, multidisciplinary, microeconomic health technology assessment
Computers & Operations Research, Volume 30, Issue 10, September 2003, Pages
1447-1465 Elliot B. Sloane, Matthew J. Liberatore, Robert L. Nydick, Wenhong Luo
and Q. B. Chung.
[45] K. L. Poh and B. W. Ang Transportation fuels and policy for Singapore: an AHP
planning approach Computers & Industrial Engineering, Volume 37, Issue 3, 1
November 1999, Pages 507-525.
[46] Yongyuan Yin and Stewart J Cohen Identifying regional goals and policy concerns
associated with global climate change Global Environmental Change, Volume 4,
Issue 3, September 1994, Pages 245-260.
[47] Annual report of the U.S. Scientific Registry of Transplant Recipients and the
Organ Procurement and Transplantation Network — transplant data: 1988–1994.
Richmond, Va.: United Network for Organ Sharing, 1995.
[48] Richard B. Freeman Jr, MD 1 *, Russell H. Wiesner 2, Ann Harper 3, Sue V.
McDiarmid 4, Jack Lake 5, Erick Edwards 3, Robert Merion 6 7, Robert Wolfe 8 9,

53

Jeremiah Turcotte 6, Lewis Teperman 2, Liver Transplantation Volume 8, Issue 9 ,
Pages 851 – 858.
[49] Tom Koch The Art of Science National transplant system: What's fair and what's
possible? OR/MS Today - October 2001.
[50] Koch, T., "Organ transplants without borders," National Post, (April 2001) pgs. A
13, 30.
[51] Koch, T., "The Limits of Principle: Deciding Who Lives and What Dies," Westport,
Conn.: Praeger Publishing, 1998
[52] Weber, E. H. (1978). The sense of touch. Academic Press for Experimental
Psychology Society. New York.
[53] Fechner, G. (1966). Elements of Psychophysics. Translated by Helmut E. Adler,
Holt, Rinehart, and Winston. New York.
[54] Saaty, Thomas L. and Vargas, Luis G. (2001). Models, Methods, Concepts and
Applications of the Analytic Hierarchy Process. Kluwer Academic Publishers.
Boston.
[55] Miller, G. A. (1956). The magical number seven plus or minus two: some limits on
out capacity for processing information. Psychological Rev. 63 81-97.
[56] Felix T.S. Chan and Niraj Kumar Global supplier development considering risk
factors using fuzzy extended AHP-based approach Omega, Volume 35, Issue 4,
August 2007, Pages 417-431.
[57] Howard, D. H. (2002). Why do transplant surgeons turn down organs?: A model of
the accept/reject decision, Journal of Health Economics 21(6): 957{969).
[58] Southard JH, Belzer FO. Organ preservation. Annu Rev Med 1995;46:235-247.

54

APPENDICES

55

Appendix A: Statistical Analytics Systems Program
/* Initializing the CPORT File and Data Extraction*/
libname lib "C:\Documents and Settings\vveerach\Desktop\SAS\newdata";
/* where you want the new data to go */
Filename tranfile 'C:\Documents and
Settings\vveerach\Desktop\newdata\LIVER_PUBLIC_USE_WLHIST_CPORT_FILE';
/* Where the transport file is stored now */
proc cimport library=lib infile=tranfile;
run;
options fmtsearch = (newlib) /* this will enable SAS to find the
formats in the catalog*/
libname lib "C:\Documents and Settings\vveerach\Desktop\SAS\newdata";
/*Extracting the value coloumns from the table*/
proc sql;
create table anew as select x.WL_ID,
x.ASCITES_DATE,
x.MELD_PELD_LAB_SCORE
from lib.Liver_wlhistory_data x;
run;
proc sql;
create table meldnew as select distinct WL_ID,Date,
meld_peld_lab_score, MELD_OR_PELD
from Anew
where meld_peld_lab_score and date is not missing;
group by wl_id;
run;

proc sort data=Anew;
by WL_ID ASCITES_DATE;
run;
data meld_prog_date;
set Anew;
by wl_id;
retain dt -1;
if first.wl_id then do;
days=0;
dt =ASCITES_DATE ;
end;
else do;
days = ASCITES_DATE - dt;
end;
drop dt;
where wl_id and ascites_date is not missing and meld_or_peld =
'MELD';
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Appendix A: (Continued)
drop meld_or_peld;
run;
proc print; run;

proc sort data=meld_prog_date out=meld_prog_date_norepli nodupkey;
by wl_id ascites_date;
run;
data MELD_Progression;
set d3;
drop ASCITES_DATE;
drop meld_or_peld;
run;

proc freq data=d3;
by wl_id;
run;

/*New Programs*/
data newtab;
set Anew;
by wl_id;
do;
days = ASCITES_DATE - MDY(01,01,1999);
end;
drop dt;
where wl_id and ascites_date is not missing;
run;
proc print; run;
data newtab_final;
set newtab;
where days >=0 and _SCORE>=6;
run;
proc sort data=newtab_final out=result2 nodupkey;
by wl_id ascites_date;
run;
proc contents data=a.a;
run;

proc sql;
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Appendix A: (Continued)
create table result3 as select WL_ID, Days, meld_peld_lab_score
from result2;
run;

/*Remove Missing*/
proc sql;
create table newtable as select distinct WL_ID,ASCITES_DATE,
MELD_PELD_LAB_SCORE
from Anew
where ASCITES_DATE and MELD_PELD_LAB_SCORE is not missing;
run;
data newtable1;
set newtable;
where ascites_date le mdy(1,1,2003);
run;

/*No Missing*/
proc sort data=newtable1 out=Followup_2003;
by descending ascites_date;
run;
proc sort data=followup_2003 nodupkey;
by wl_id;
run;

proc sql;
create table new as select distinct WL_ID,ASCITES_DATE,
MELD_PELD_LAB_SCORE
from Anew
where ASCITES_DATE and MELD_PELD_LAB_SCORE is not missing;
run;
data new1;
set new;
where ascites_date le mdy(1,1,2002);
run;

/*No Missing*/
proc sort data=new1 out=Followup_2002;
by descending ascites_date;
run;
proc sort data=followup_2002 nodupkey;
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Appendix A: (Continued)
by wl_id;
run;
/*Coverting days from January 2002 to number of days*/
data newtab;
set followup_2002;
do;
days = ASCITES_DATE - MDY(01,01,2002);
end;
run;
proc sql;
create table finalfinal as select WL_ID, Days, meld_peld_lab_score
from newtab;
run;
/*Start New 2002 2003 2004 2005 */
data new1;
set new;
where ascites_date le mdy(1,1,2003);
run;

/*No Missing*/
proc sort data=new1 out=Followup_2003;
by descending ascites_date;
run;
proc sort data=followup_2003 nodupkey;
by wl_id;
run;

data newtab2003;
set followup_2003;
do;
days = ASCITES_DATE - MDY(01,01,2002);
end;
run;
proc sql;
create table final_followup_2003 as select WL_ID, Days,
meld_peld_lab_score
from newtab2003;
run;

data new1;
set new;
where ascites_date le mdy(1,1,2004);
run;
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Appendix A: (Continued)
/*Sorting and Ascending by removing the duplicates Missing*/
proc sort data=new1 out=Followup_2004;
by descending ascites_date;
run;
proc sort data=followup_2004 nodupkey;
by wl_id;
run;

data newtab2004;
set followup_2004;
do;
days = ASCITES_DATE - MDY(01,01,2002);
end;
run;
proc sql;
create table final_followup_2004 as select WL_ID, Days,
meld_peld_lab_score
from newtab2004;
run;

data new1;
set new;
where ascites_date le mdy(1,1,2005);
run;

/*No Missing*/
proc sort data=new1 out=Followup_2005;
by descending ascites_date;
run;
proc sort data=followup_2005 nodupkey;
by wl_id;
run;

data newtab2005;
set followup_2005;
do;
days = ASCITES_DATE - MDY(01,01,2002);
end;
run;
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Appendix A: (Continued)
proc sql;
create table final_followup_2005 as select WL_ID, Days,
meld_peld_lab_score
from newtab2005;
run;

/*Meld And PELD SCORE*/
data End2002;
set Final_followup_2002;
where MELD_PELD_LAB_SCORE>=6;
run;

data End2003;
set Final_followup_2003;
where MELD_PELD_LAB_SCORE>=6;
run;
data End2004;
set Final_followup_2004;
where MELD_PELD_LAB_SCORE>=6;
run;
data End2005;
set Final_followup_2005;
where MELD_PELD_LAB_SCORE>=6;
run;

/*CHANGE IN MONDAY*/
Data FINAL_FOLLOW_UP;
set followup_all;
by wl_id;
do;
days = ASCITES_DATE - MDY(01,01,2002);
end;
drop dt;
where wl_id and ascites_date is not missing;
retain ascites_date;
run;
proc sql;
create table final_all_all as select WL_ID, Days, meld_peld_lab_score
from final_follow_up;
run;
data final_all;
set final_all_all;
where days >0;
run;
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Appendix A: (Continued)
proc sort data=final_all nodupkey;
by wl_id days;
run;

PROC SORT DATA=a.Final_2003;
BY wl_id;
PROC SORT DATA=a.Final_followup_2003;
BY wl_id;
DATA widedata;
MERGE a.final_2003 a.Final_followup_2003;
BY wl_id;
RUN;
/*Merging the data sets from Patient Registration and patient follow up
database*/
data three;
merge a.Final_2003(in=fromdadx)
a.Final_followup_2003(in=fromfamx);
by wl_id;
fromdad = fromdadx;
fromfam = fromfamx;
if fromdad=1 and fromfam=1;
run;
PROC FREQ DATA=three;
TABLES fromdad*fromfam;
where fromdad=1 and fromfam=1;
RUN;
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Appendix B: Donor and Transplant OPO
Table B.1 Transplant OPO vs. Donor OPO
No

Transplant OPO

Donor OPO

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

ALOB-OP1
AROR-OP1 11
AZOB-OP1
CADN-OP1
CAGS-OP1
CAOP-OP1
CARO-OP1
CASD-IO1
CORS-OP1
CTOP-OP1
DCTC-OP1
FLMP-OP1
FLUF-IO1
FLWC-OP1
GALL-OP1
HIOP-OP1
IAOP-OP1
ILIP-OP1
INOP-OP1
KYDA-OP1
LAOP-OP1
MAOB-OP1
MDPC-OP1
MIOP-OP1
MNOP-OP1
MOMA-OP1
MSOP-OP1
MWOB-OP1
NCCM-IO1
NCNC-OP1
NEOR-OP1
NJTO-OP1
NMOP-OP1
NYFL-IO1
NYRT-OP1
OHLB-OP1
OHLC-OP1 12
OHLP-OP1
OHOV-OP1
OKOP-OP1
ORUO-IO1
PADV-OP1
PATF-OP1
SCOP-OP1

ALOB-OP1
AROR-OP1
AZOB-OP1
CADN-OP1
CAGS-OP1
CAOP-OP1
CARO-OP1
CASD-IO1
CORS-OP1
CTOP-OP1
DCTC-OP1
FLFH-IO1
FLMP-OP1
FLSW-OP1
FLUF-IO1
FLWC-OP1
GALL-OP1
GAMC-IO1
HIOP-OP1
IAIV-IO1
IAOP-OP1
ILCL-OP1
ILCR-OP1
ILIP-OP1
INOP-OP1
KYDA-OP1
LAOC-OP1
LAOP-OP1
LAOS-OP1
LASU-IO1
MAOB-OP1
MDPC-OP1
MIOP-OP1
MNOP-OP1
MNRC-OP1
MOMA-OP1
MSOP-OP1
MWOB-OP1
NCBG-IO1
NCCM-IO1
NCNC-OP1
NEOR-OP1
NJTO-OP1
NMOP-OP1
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Appendix B: Donor and Transplant OPO
Table B.1 (Continued)
No

Transplant OPO

Donor OPO

45
46
47
48
49
50
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86

TNDS-OP1
TNMS-OP1
TXGC-OP1
TXSA-OP1
TXSB-OP1
UTOP-OP1
VAOP-OP1
VATB-OP1
WALC-OP1
WANW-OP1
WISE-IO1
WIUW-IO1

NVLV-OP1
NYAP-OP1
NYFL-IO1
NYRC-OP1
NYRT-OP1
NYSB-IO1
OHLB-OP1
OHLC-OP1
OHLP-OP1
OHMV-IO1
OHOV-OP1
OKHM-IO1
OKOP-OP1
ORUO-IO1
PADV-OP1
PATF-OP1
PRLL-OP1
SCOP-OP1
TNDS-OP1
TNET-OP1
TNMS-OP1
TXAD-IO1
TXBC-IO1
TXFW-IO1
TXGC-OP1
TXLG-IO1
TXSA-OP1
TXSB-OP1
UNKN-OP1
UTOP-OP1
VAFH-IO1
VAOP-OP1
VATB-OP1
WALC-OP1
WANW-OP1
WASH-IO1
WISE-IO1
WISL-IO1
WIUW-IO1
WVMS-OP1
ZCAN-FOP

87

ZFOR-FOP
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Appendix C: Cold Ischemic Time Vs Distance
Table C.1 Analysis for 0 - 5000 in range of 100 miles
Analysis for 0 - 5000 in range of 100 miles
Mean
CIT
Distance - Miles
LCL
UCL
0 - 100
8.0399
7.9931 8.087
100 - 200
9.2977
9.2149 9.38
200 - 300
9.8012
9.6868 9.916
300 - 400
10.0359
9.8478 10.22
400 - 500
10.1749
9.9574 10.39
500 - 600
10.3177
10.066 10.57
600 - 700
10.8373
10.542 11.13
700 - 800
11.1372
10.816 11.46
800 - 900
10.8209
10.495 11.15
900 - 1000
11.9619
11.467 12.46
1000 - 1100
10.8845
10.425 11.35
1100 - 1200
11.6717
11.118 12.23
1200 - 1300
11.5631
10.887 12.24
1300 - 1400
11.6803
10.831 12.53
1400 - 1500
12.3073
11.746 12.87
1500 - 1600
13.0943
12.239 13.95
1600 - 1700
13.3862
12.533 14.24
1700 - 1800
13.096
12.307 13.89
1800 - 1900
15.0422
14.351 15.73
1900 - 2000
15.5607
14.483 16.63
2000 - 2100
14.1942
13.371 15.02
2100 - 2200
13.9505
12.719 15.18
2200 - 2300
13.2455
12.156 14.34
2300- 2400
14.3079
11.91 16.71
2400 - 2500
8.775
2.6667 14.88

SD
4.5655
4.398
4.5425
5.2455
4.867
5.2922
4.8056
4.8368
4.9589
5.2669
4.7745
4.4073
5.8062
5.2437
3.9215
5.6182
5.2145
3.8089
5.2262
5.563
5.2225
6.2371
4.5704
4.9756
3.8387

Var
20.8438
19.3424
20.6343
27.5153
23.6877
28.0074
23.0938
23.3946
24.5907
27.7402
22.7959
19.4243
33.712
27.4964
15.3782
31.5642
27.191
14.5077
27.3132
30.947
27.2745
38.9014
20.8886
24.7566
14.7356

Range
50
150
250
350
450
550
650
750
850
950
1050
1150
1250
1350
1450
1550
1650
1750
1850
1950
2050
2150
2250
2350
2450

Only 14 readings for distance between the transplant centers greater than 2500.
Analysis for 0 - 500 miles in range of 50 miles
Distance - Miles
Mean
LCL
UCL
0 - 50
7.7897
7.7351 7.844
50 - 100
8.7992
8.7119 8.887
100 - 150
9.247
9.1358 9.358
150 - 200
9.4103
9.293 9.528
200 - 250
9.6498
9.5067 9.793
250 - 300
9.96
9.7771 10.14
300 - 350
9.7486
9.498 9.999
350 - 400
10.3845
10.107 10.66
400 - 450
10.262
9.9587 10.57
450 - 500
10.0516
9.7451 10.36

SD
4.6128
4.3447
4.3716
4.4444
4.434
4.6427
5.2697
5.2251
4.9757
4.7187
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Var
21.2779
18.8764
19.1109
19.7527
19.6604
21.5547
27.7697
27.3017
24.7576
22.2661

Range
25
75
125
175
225
275
325
375
425
475

Appendix C: (Continued)
Table C.2 ANOVA Table for Patients Arrivals
SUMMARY OUTPUT
Regression Statistics
Multiple R
0.8874623
R Square
0.7875894
Adjusted R
Square
0.761038
Standard Error
0.3801294
Observations
10
ANOVA
Df
1
8
9

SS
4.2862407
1.1559871
5.442227

Coefficients
8.39059
0.00455

Standard
Error
0.24132
0.00083

Regression
Residual
Total

Intercept
X Variable 1

MS
4.28624
0.1445

F
29.6629

Significance
F
0.000611

t Stat
34.769
5.44637

P-value
5.1E-10
0.00061

Lower 95%
7.83410
0.00262

Upper
95%
8.9470
0.0064

Lower
95.0%
7.83410
0.00262

Patients

Arrival Candidates/ MELD Score /OPO
40
35
30
25
20
15
10
5
0

Transplant Candidate
/ MELD Score

1

4

7

10 13 16 19 22 25 28 31 34
MELD Score

Figure C.1 Arrival of MELD Patients / OPO

66

Upper
95.0%
8.9470
0.0064

Appendix C: (Continued)
Table C.3 ANOVA for Distance vs. CIT
SUMMARY OUTPUT
Regression Statistics
Multiple R
0.7255
R Square
0.5263
Adjusted R
0.5057
Square
Standard
1.3935
Error
Observations

25

ANOVA

Regression
Residual
Total

Df
1
23
24

SS
49.627
44.662
94.289

Intercept

Coefficients
9.3651

Standard
Error
0.5577

X Variable 1

0.002

0.0004

F
25.56

Significance
F
4.066E-05

t Stat
16.791

Pvalue
2E-14

Lower 95%
8.2113027

Upper
95%
10.51882

Lower
95.0%
8.211303

Upper
95.0%
10.51882

5.0554

4E-05

0.0011543

0.002753

0.001154

0.002753

MS
49.627
1.9418

Distance by CIT

CIT Hours

20
15
Distance by CIT

10
5
0
0

500

1000

1500

2000

Distance in Miles

Figure C.2 Distance vs. CIT 100 miles
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